IMNN Imunon reports positive phase 2 mrd clinical data for imnn-001, demonstrating the successful overcoming of historical il-12 safety barr

IMNN Imunon reports positive phase 2 mrd clinical data for imnn-001, demonstrating the successful overcoming of historical il-12 safety barriers in frontline ovarian cancer Imunon - imnn-001 demonstrates lower mrd rate, higher ctdna clearance, and higher Ned rate vs control - Imnn-001 shows highly favorable safety and tolerability profile - No cytokine release syndrome or serious immune-related adverse events observed with imnn-001 - Imnn-001 under evaluation in phase 3 ovation 3 trial for advanced ovarian cancer